The impact of a FRAX-based intervention threshold in Turkey: The FRAX-TURK study

Archives of Osteoporosis

Volumn 7, Issue 1-2, 2012, Pages 229-235

  Tuzun, Sansin ^a,d   Eskiyurt, Nurten ^b,d   Akarirmak, Ulku ^a,d   Saridogan, Merih ^a,d   Johansson, Helena ^c,d   McCloskey, Eugene ^c,d   Kanis, John A ^c,d  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d Turkish Osteoporosis Society   (Turkey)

Author keywords

Assessment thresholds; BMD; Clinical guidelines; Fracture probability; FRAX; Intervention threshold

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; FEMALE; FRAGILITY FRACTURE; GENDER; HEALTH IMPACT ASSESSMENT; HIP FRACTURE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; TREATMENT INDICATION; TURKEY (REPUBLIC);

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALGORITHMS; BODY MASS INDEX; BONE DENSITY; DENSITOMETRY; FEMALE; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; TURKEY;

EID: 84876288917     PISSN: 18623522     EISSN: 18623514     Source Type: Journal    
DOI: 10.1007/s11657-012-0101-4     Document Type: Article

References (39)

1. Kanis JA on behalf of the World Health Organization Scientific Group (2008a) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. http://www.shef.ac.uk/FRAX/index.htm. Accessed 3 Mar 2012
2. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989-995
3. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431-1444
4. Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractures Scores. Br Med J 339:b4229
5. Kanis JA, Hans D, Cooper C, Task Force of the FRAX Initiative (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:395-411
6. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385-397
7. Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033-1046
8. Kanis JA, Odén A, McCloskey EV, IOF Working Group on Epidemiology and Quality of Life et al (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. doi: 10.1007s00198-012- 1964-3
9. Elffors I, Allander E, Kanis JA et al (1994) The variable incidence of hip fracture in Southern Europe: the MEDOS Study. Osteoporosis Int 4:253-263
10. Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M, Johansson H et al (2012) Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporos Int 23:949-955
11. Compston J, Cooper A, Cooper C, on behalf of the National Osteoporosis Guideline Group (NOGG) et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105-108
12. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A, the National Osteoporosis Guideline Group (2008) Case finding for the management of osteoporosis with FRAX® - assessment and intervention thresholds for the UK. Osteoporos Int 19:1395-1408, Erratum 2009 Osteoporos Int 20, 499-502
13. Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864-1873
14. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D, on behalf of the European Foundation for Osteoporosis and Bone Disease (1997) Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390-406
15. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428
16. National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation. www.nof.org
17. European Community (1998) Report on osteoporosis in the European Community. 1998. EC, Strasbourg
18. Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. Royal College of Physicians, London
19. Brixen K (2002) Consensus report on osteoporosis. Ugeskrift for Laeger, 2002, Suppl. 10.
20. Hellenic Foundation for Osteoporosis (2004) Kateufunthries gpammes gia th diagnwsh kai antimetwpisnh ths Osteopowshs sthn Ellada 2004 [Guidelines for diagnosis and management of osteoporosis in Greece 2004]. Athens
21. Collegio dei Reumatologi Ospedalieri (CROI), Società Italiana dell'Osteoporosi e delle Malattie del Metabolismo Minerale e Scheletrico (SIOMMMS), Società Italiana di Medicina Fisica e Riabilitativa (SIMFER), Società Italiana di Medicina Interna (SIMI), Società Italiana di Ortopedia e Traumatologia (SIOT), Società Italiana di Radiologia Medica (SIRM), Società Italiana di Reumatologia (SIR). (2006) Linee guida per la diagnosi, prevenzione e terapia dell'osteoporosi [Guidelines for the diagnosis, prevention and treatment of osteoporosis] Pavia, SINOSSI. EDIMES
22. Pols HA, Wittenberg J (2002) CBO guideline: osteoporosis. Nederlands Tijdschrift voor Geneeskunde 2002(146):1359-1363
23. Sociedad Española de Investigaciones Óseas Y Metabolismo Mineral (SEIOMM) (2003) Guía de Práctica: osteoporosis posmenopáusica [Practice guidelines:postmenopausal osteoporosis]. Revista Clinica Española, 203: 496-506. www.seiomm.org. Accessed 14 Nov 2006
24. SIGN (2003) Management of osteoporosis. Edinburgh, Scottish Intercollegiate Guidelines Network. www.sign.ac.uk. Accessed 14 Nov 2006
25. Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1-256
26. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, National Osteoporosis Foundation Guide Committee et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437-447
27. Lekawasam S, Adachi JD, Agnusdei D F et al. for the Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (in press)
28. Johansson H, Oden A, Johnell O et al (2004) Optimisation of BMD measurements to identify high risk groups for treatment - a test analysis. J Bone Miner Res 19:906-913
29. Turkey National Statistical Office (2009) TUIK-Turkey. http://report.tuik.gov.tr/reports/rwservlet?adnksdb2=&report=turkiye-yasgr. RDF&p-yil=2009&p-dil=1&desformat=html&ENVID=adnksdb2Env. Accessed 3 March 2012
30. Kobak S (2011) Demographic, clinical, and serological features of Turkish patients with rheumatoid arthritis: evaluation of 165 patients. Clin Rheumatol 30:843-847
31. United Nations (2010) Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, World Population Prospects: http://esa.un.org/unpd/wpp/unpp/panel-indicators.htm. Accessed Nov 2011
32. Kanis JA McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2012) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (in press)
33. Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 20:1675-1682
34. Johansson H, Kanis JA, Oden A, Johnell O, Compston J, McCloskey EV (2012) A comparison of case finding strategies in the UK for the management of hip fractures. Osteoporos Int 23:907-915
35. Leslie WD, Lix LM, Majumdar SR et al (2011) High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 23:391-397
36. Leslie WD, Lix LM, Morin S, Johnansson H, Odén A, McCloskey E, Kanis JA (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23:75-85
37. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX® with and without BMD. Calcif Tiss Int 90:1-13
38. Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423-431
39. Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4-15